Literature DB >> 33035641

SOS GEFs in health and disease.

Fernando C Baltanás1, Natasha Zarich2, Jose M Rojas-Cabañeros2, Eugenio Santos3.   

Abstract

SOS1 and SOS2 are the most universal and widely expressed family of guanine exchange factors (GEFs) capable or activating RAS or RAC1 proteins in metazoan cells. SOS proteins contain a sequence of modular domains that are responsible for different intramolecular and intermolecular interactions modulating mechanisms of self-inhibition, allosteric activation and intracellular homeostasis. Despite their homology, analyses of SOS1/2-KO mice demonstrate functional prevalence of SOS1 over SOS2 in cellular processes including proliferation, migration, inflammation or maintenance of intracellular redox homeostasis, although some functional redundancy cannot be excluded, particularly at the organismal level. Specific SOS1 gain-of-function mutations have been identified in inherited RASopathies and various sporadic human cancers. SOS1 depletion reduces tumorigenesis mediated by RAS or RAC1 in mouse models and is associated with increased intracellular oxidative stress and mitochondrial dysfunction. Since WT RAS is essential for development of RAS-mutant tumors, the SOS GEFs may be considered as relevant biomarkers or therapy targets in RAS-dependent cancers. Inhibitors blocking SOS expression, intrinsic GEF activity, or productive SOS protein-protein interactions with cellular regulators and/or RAS/RAC targets have been recently developed and shown preclinical and clinical effectiveness blocking aberrant RAS signaling in RAS-driven and RTK-driven tumors.
Copyright © 2020 The Author(s). Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer; RAS; RASGEF; Rasopathies; SOS1; SOS2

Mesh:

Substances:

Year:  2020        PMID: 33035641     DOI: 10.1016/j.bbcan.2020.188445

Source DB:  PubMed          Journal:  Biochim Biophys Acta Rev Cancer        ISSN: 0304-419X            Impact factor:   10.680


  13 in total

Review 1.  Neurodevelopmental disorders, immunity, and cancer are connected.

Authors:  Ruth Nussinov; Chung-Jung Tsai; Hyunbum Jang
Journal:  iScience       Date:  2022-05-30

Review 2.  Drug resistance in targeted cancer therapies with RAF inhibitors.

Authors:  Ufuk Degirmenci; Jiajun Yap; Yuen Rong M Sim; Shiru Qin; Jiancheng Hu
Journal:  Cancer Drug Resist       Date:  2021-06-17

Review 3.  40 Years of RAS-A Historic Overview.

Authors:  Alberto Fernández-Medarde; Javier De Las Rivas; Eugenio Santos
Journal:  Genes (Basel)       Date:  2021-05-01       Impact factor: 4.096

4.  Functional Specificity of the Members of the Sos Family of Ras-GEF Activators: Novel Role of Sos2 in Control of Epidermal Stem Cell Homeostasis.

Authors:  Fernando C Baltanás; Cynthia Mucientes-Valdivieso; L Francisco Lorenzo-Martín; Natalia Fernández-Parejo; Rósula García-Navas; Carmen Segrelles; Nuria Calzada; Rocío Fuentes-Mateos; Jesús M Paramio; Xosé R Bustelo; Eugenio Santos
Journal:  Cancers (Basel)       Date:  2021-04-29       Impact factor: 6.639

5.  How can same-gene mutations promote both cancer and developmental disorders?

Authors:  Ruth Nussinov; Chung-Jung Tsai; Hyunbum Jang
Journal:  Sci Adv       Date:  2022-01-14       Impact factor: 14.136

Review 6.  Proliferation and Apoptosis Pathways and Factors in Oral Squamous Cell Carcinoma.

Authors:  Steven He; Rajdeep Chakraborty; Shoba Ranganathan
Journal:  Int J Mol Sci       Date:  2022-01-29       Impact factor: 5.923

Review 7.  The Crossroads between RAS and RHO Signaling Pathways in Cellular Transformation, Motility and Contraction.

Authors:  Olga Soriano; Marta Alcón-Pérez; Miguel Vicente-Manzanares; Esther Castellano
Journal:  Genes (Basel)       Date:  2021-05-27       Impact factor: 4.096

8.  Crk adaptor proteins are necessary for the development of the zebrafish retina.

Authors:  Helaina R Stergas; Zoë Kalbag; Riley M St Clair; Jared C Talbot; Bryan A Ballif; Alicia M Ebert
Journal:  Dev Dyn       Date:  2021-07-24       Impact factor: 2.842

Review 9.  Targeting KRAS mutant lung cancer: light at the end of the tunnel.

Authors:  Matthias Drosten; Mariano Barbacid
Journal:  Mol Oncol       Date:  2022-01-18       Impact factor: 6.603

10.  Critical requirement of SOS1 RAS-GEF function for mitochondrial dynamics, metabolism, and redox homeostasis.

Authors:  Rósula García-Navas; Pilar Liceras-Boillos; Carmela Gómez; Fernando C Baltanás; Nuria Calzada; Cristina Nuevo-Tapioles; José M Cuezva; Eugenio Santos
Journal:  Oncogene       Date:  2021-06-12       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.